Which has higher valuation & earnings, JSPR or ACRV?

Acrivon Therapeutics is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Jasper Therapeutics N/A N/A -$75.80M -$1.59 N/A Acrivon Therapeutics N/A N/A -$77.90M -$1.88 N/A

Is JSPR or ACRV more profitable?

Acrivon Therapeutics' return on equity of -70.14% beat Jasper Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Jasper Therapeutics N/A -884.17% -143.83% Acrivon Therapeutics N/A -70.14% -61.60%

Do analysts rate JSPR or TELO?

Jasper Therapeutics presently has a consensus price target of $8.17, indicating a potential upside of 1,305.86%. Given Jasper Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Jasper Therapeutics is more favorable than Telomir Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jasper Therapeutics 1 Sell rating(s) 3 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.50 Telomir Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better earnings and valuation, JSPR or TELO?

Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Jasper Therapeutics N/A N/A -$75.80M -$1.59 N/A Telomir Pharmaceuticals N/A N/A -$10.41M -$0.91 N/A

Is JSPR or TELO more profitable?

Telomir Pharmaceuticals' return on equity of -102.70% beat Jasper Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Jasper Therapeutics N/A -884.17% -143.83% Telomir Pharmaceuticals N/A -102.70% -90.75%

Does the media prefer JSPR or TELO?

In the previous week, Telomir Pharmaceuticals had 1 more articles in the media than Jasper Therapeutics. MarketBeat recorded 3 mentions for Telomir Pharmaceuticals and 2 mentions for Jasper Therapeutics. Jasper Therapeutics' average media sentiment score of 0.63 beat Telomir Pharmaceuticals' score of 0.62 indicating that Jasper Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jasper Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Telomir Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, KLRS or JSPR?

Kalaris Therapeutics is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kalaris Therapeutics N/A N/A -$43.44M -$2.02 N/A Jasper Therapeutics N/A N/A -$75.80M -$1.59 N/A

Is KLRS or JSPR more profitable?

Kalaris Therapeutics' return on equity of -71.71% beat Jasper Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Kalaris Therapeutics N/A -71.71% -42.95% Jasper Therapeutics N/A -884.17% -143.83%

Does the media favor KLRS or JSPR?

In the previous week, Kalaris Therapeutics had 1 more articles in the media than Jasper Therapeutics. MarketBeat recorded 3 mentions for Kalaris Therapeutics and 2 mentions for Jasper Therapeutics. Jasper Therapeutics' average media sentiment score of 0.63 beat Kalaris Therapeutics' score of 0.62 indicating that Jasper Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kalaris Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Jasper Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to JSPR or SERA?

In the previous week, Sera Prognostics had 6 more articles in the media than Jasper Therapeutics. MarketBeat recorded 8 mentions for Sera Prognostics and 2 mentions for Jasper Therapeutics. Jasper Therapeutics' average media sentiment score of 0.63 beat Sera Prognostics' score of 0.44 indicating that Jasper Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jasper Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sera Prognostics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is IBIO or JSPR more profitable?

iBio's return on equity of -40.66% beat Jasper Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets iBio N/A -40.66% -35.78% Jasper Therapeutics N/A -884.17% -143.83%

Does the media prefer IBIO or JSPR?

In the previous week, iBio had 1 more articles in the media than Jasper Therapeutics. MarketBeat recorded 3 mentions for iBio and 2 mentions for Jasper Therapeutics. Jasper Therapeutics' average media sentiment score of 0.63 beat iBio's score of 0.40 indicating that Jasper Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment iBio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Jasper Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Jasper Therapeutics (JSPR) Competitors

$0.58 +0.01 (+1.89%)

Closing price 04:00 PM Eastern

Extended Trading

$0.58 0.00 (-0.15%)

As of 06:45 PM Eastern

Compare

JSPR vs. ACRV, TELO, KLRS, SERA, and IBIO

Should you buy Jasper Therapeutics stock or one of its competitors? Jasper Therapeutics's main competitors and comparable companies include Acrivon Therapeutics (ACRV), Telomir Pharmaceuticals (TELO), Kalaris Therapeutics (KLRS), Sera Prognostics (SERA), and iBio (IBIO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Jasper Therapeutics compare to Acrivon Therapeutics?

Jasper Therapeutics (NASDAQ:JSPR) and Acrivon Therapeutics (NASDAQ:ACRV) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.

Acrivon Therapeutics is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jasper Therapeutics	N/A	N/A	-$75.80M	-$1.59	N/A
Acrivon Therapeutics	N/A	N/A	-$77.90M	-$1.88	N/A

In the previous week, Jasper Therapeutics had 1 more articles in the media than Acrivon Therapeutics. MarketBeat recorded 2 mentions for Jasper Therapeutics and 1 mentions for Acrivon Therapeutics. Acrivon Therapeutics' average media sentiment score of 1.43 beat Jasper Therapeutics' score of 0.63 indicating that Acrivon Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Jasper Therapeutics	Positive
Acrivon Therapeutics	Positive

Jasper Therapeutics currently has a consensus price target of $8.17, indicating a potential upside of 1,305.86%. Acrivon Therapeutics has a consensus price target of $13.50, indicating a potential upside of 694.12%. Given Jasper Therapeutics' higher possible upside, analysts plainly believe Jasper Therapeutics is more favorable than Acrivon Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jasper Therapeutics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50
Acrivon Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Acrivon Therapeutics' return on equity of -70.14% beat Jasper Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jasper Therapeutics	N/A	-884.17%	-143.83%
Acrivon Therapeutics	N/A	-70.14%	-61.60%

Jasper Therapeutics has a beta of 3.04, suggesting that its share price is 204% more volatile than the broader market. Comparatively, Acrivon Therapeutics has a beta of 1.92, suggesting that its share price is 92% more volatile than the broader market.

79.9% of Jasper Therapeutics shares are held by institutional investors. Comparatively, 71.6% of Acrivon Therapeutics shares are held by institutional investors. 3.9% of Jasper Therapeutics shares are held by insiders. Comparatively, 10.5% of Acrivon Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Jasper Therapeutics beats Acrivon Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Jasper Therapeutics compare to Telomir Pharmaceuticals?

Jasper Therapeutics (NASDAQ:JSPR) and Telomir Pharmaceuticals (NASDAQ:TELO) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk, valuation and media sentiment.

Telomir Pharmaceuticals' return on equity of -102.70% beat Jasper Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jasper Therapeutics	N/A	-884.17%	-143.83%
Telomir Pharmaceuticals	N/A	-102.70%	-90.75%

79.9% of Jasper Therapeutics shares are held by institutional investors. 3.9% of Jasper Therapeutics shares are held by insiders. Comparatively, 16.4% of Telomir Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Jasper Therapeutics presently has a consensus price target of $8.17, indicating a potential upside of 1,305.86%. Given Jasper Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Jasper Therapeutics is more favorable than Telomir Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jasper Therapeutics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Telomir Pharmaceuticals had 1 more articles in the media than Jasper Therapeutics. MarketBeat recorded 3 mentions for Telomir Pharmaceuticals and 2 mentions for Jasper Therapeutics. Jasper Therapeutics' average media sentiment score of 0.63 beat Telomir Pharmaceuticals' score of 0.62 indicating that Jasper Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jasper Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Telomir Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jasper Therapeutics	N/A	N/A	-$75.80M	-$1.59	N/A
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.91	N/A

Jasper Therapeutics has a beta of 3.04, suggesting that its stock price is 204% more volatile than the broader market. Comparatively, Telomir Pharmaceuticals has a beta of -0.25, suggesting that its stock price is 125% less volatile than the broader market.

Summary

Jasper Therapeutics beats Telomir Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Jasper Therapeutics compare to Kalaris Therapeutics?

Kalaris Therapeutics (NASDAQ:KLRS) and Jasper Therapeutics (NASDAQ:JSPR) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends.

Kalaris Therapeutics has a beta of 0.22, meaning that its share price is 78% less volatile than the broader market. Comparatively, Jasper Therapeutics has a beta of 3.04, meaning that its share price is 204% more volatile than the broader market.

Kalaris Therapeutics' return on equity of -71.71% beat Jasper Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kalaris Therapeutics	N/A	-71.71%	-42.95%
Jasper Therapeutics	N/A	-884.17%	-143.83%

Kalaris Therapeutics is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kalaris Therapeutics	N/A	N/A	-$43.44M	-$2.02	N/A
Jasper Therapeutics	N/A	N/A	-$75.80M	-$1.59	N/A

In the previous week, Kalaris Therapeutics had 1 more articles in the media than Jasper Therapeutics. MarketBeat recorded 3 mentions for Kalaris Therapeutics and 2 mentions for Jasper Therapeutics. Jasper Therapeutics' average media sentiment score of 0.63 beat Kalaris Therapeutics' score of 0.62 indicating that Jasper Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kalaris Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Jasper Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kalaris Therapeutics currently has a consensus price target of $18.75, suggesting a potential upside of 489.62%. Jasper Therapeutics has a consensus price target of $8.17, suggesting a potential upside of 1,305.86%. Given Jasper Therapeutics' higher possible upside, analysts clearly believe Jasper Therapeutics is more favorable than Kalaris Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kalaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Jasper Therapeutics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50

66.1% of Kalaris Therapeutics shares are owned by institutional investors. Comparatively, 79.9% of Jasper Therapeutics shares are owned by institutional investors. 68.1% of Kalaris Therapeutics shares are owned by insiders. Comparatively, 3.9% of Jasper Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Kalaris Therapeutics and Jasper Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Jasper Therapeutics compare to Sera Prognostics?

Jasper Therapeutics (NASDAQ:JSPR) and Sera Prognostics (NASDAQ:SERA) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, media sentiment, profitability, dividends, analyst recommendations and valuation.

Jasper Therapeutics has a beta of 3.04, meaning that its stock price is 204% more volatile than the broader market. Comparatively, Sera Prognostics has a beta of 0.98, meaning that its stock price is 2% less volatile than the broader market.

79.9% of Jasper Therapeutics shares are owned by institutional investors. Comparatively, 54.6% of Sera Prognostics shares are owned by institutional investors. 3.9% of Jasper Therapeutics shares are owned by insiders. Comparatively, 11.3% of Sera Prognostics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Jasper Therapeutics has a net margin of 0.00% compared to Sera Prognostics' net margin of -47,475.72%. Sera Prognostics' return on equity of -46.71% beat Jasper Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jasper Therapeutics	N/A	-884.17%	-143.83%
Sera Prognostics	-47,475.72%	-46.71%	-34.06%

Sera Prognostics has higher revenue and earnings than Jasper Therapeutics. Sera Prognostics is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jasper Therapeutics	N/A	N/A	-$75.80M	-$1.59	N/A
Sera Prognostics	$80K	996.11	-$31.93M	-$0.67	N/A

In the previous week, Sera Prognostics had 6 more articles in the media than Jasper Therapeutics. MarketBeat recorded 8 mentions for Sera Prognostics and 2 mentions for Jasper Therapeutics. Jasper Therapeutics' average media sentiment score of 0.63 beat Sera Prognostics' score of 0.44 indicating that Jasper Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jasper Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sera Prognostics	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Jasper Therapeutics currently has a consensus target price of $8.17, suggesting a potential upside of 1,305.86%. Sera Prognostics has a consensus target price of $5.50, suggesting a potential upside of 172.28%. Given Jasper Therapeutics' higher probable upside, equities research analysts clearly believe Jasper Therapeutics is more favorable than Sera Prognostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jasper Therapeutics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50
Sera Prognostics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Summary

Sera Prognostics beats Jasper Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Jasper Therapeutics compare to iBio?

iBio (NASDAQ:IBIO) and Jasper Therapeutics (NASDAQ:JSPR) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, valuation, profitability, earnings, institutional ownership and media sentiment.

7.9% of iBio shares are owned by institutional investors. Comparatively, 79.9% of Jasper Therapeutics shares are owned by institutional investors. 1.6% of iBio shares are owned by insiders. Comparatively, 3.9% of Jasper Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

iBio has higher revenue and earnings than Jasper Therapeutics. iBio is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iBio	$100K	758.82	-$33.04M	-$0.34	N/A
Jasper Therapeutics	N/A	N/A	-$75.80M	-$1.59	N/A

iBio currently has a consensus price target of $5.00, indicating a potential upside of 323.73%. Jasper Therapeutics has a consensus price target of $8.17, indicating a potential upside of 1,305.86%. Given Jasper Therapeutics' higher probable upside, analysts clearly believe Jasper Therapeutics is more favorable than iBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iBio	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13
Jasper Therapeutics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50

iBio's return on equity of -40.66% beat Jasper Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iBio	N/A	-40.66%	-35.78%
Jasper Therapeutics	N/A	-884.17%	-143.83%

In the previous week, iBio had 1 more articles in the media than Jasper Therapeutics. MarketBeat recorded 3 mentions for iBio and 2 mentions for Jasper Therapeutics. Jasper Therapeutics' average media sentiment score of 0.63 beat iBio's score of 0.40 indicating that Jasper Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iBio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Jasper Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

iBio has a beta of 1.29, suggesting that its stock price is 29% more volatile than the broader market. Comparatively, Jasper Therapeutics has a beta of 3.04, suggesting that its stock price is 204% more volatile than the broader market.

Summary

iBio beats Jasper Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Jasper Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding JSPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

JSPR vs. The Competition

Export

Metric	Jasper Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$19.33M	$3.83B	$7.19B	$14.92B
Dividend Yield	N/A	3.65%	2.57%	11.71%
P/E Ratio	-0.37	14.40	274.09	25.35
Price / Sales	N/A	1,415.91	697.83	112.39
Price / Cash	N/A	108.94	77.71	51.48
Price / Book	3.87	15.15	10.37	6.25
Net Income	-$75.80M	-$22.78M	$3.49B	$358.55M
7 Day Performance	-17.13%	-3.96%	-1.78%	-2.07%
1 Month Performance	-26.48%	-2.59%	-1.48%	-4.80%
1 Year Performance	-76.09%	37.19%	18.20%	5.44%

Jasper Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
JSPR Jasper Therapeutics	2.0473 of 5 stars	$0.58 +1.9%	$8.17 +1,305.9%	-76.1%	$19.33M	N/A	N/A	20	News Coverage
ACRV Acrivon Therapeutics	3.9951 of 5 stars	$1.96 -2.0%	$13.50 +588.8%	+21.2%	$83.99M	N/A	N/A	58	Positive News
TELO Telomir Pharmaceuticals	0.3515 of 5 stars	$1.17 flat	N/A	-12.0%	$80.47M	N/A	N/A	1
KLRS Kalaris Therapeutics	3.3925 of 5 stars	$3.30 -2.4%	$18.75 +468.2%	-13.7%	$80.46M	N/A	N/A	110	Analyst Downgrade
SERA Sera Prognostics	2.4648 of 5 stars	$2.00 -1.5%	$5.50 +175.0%	-35.8%	$80.08M	$70K	N/A	120

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:JSPR) was last updated on 9/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Jasper Therapeutics (JSPR) Competitors

JSPR vs. ACRV, TELO, KLRS, SERA, and IBIO

How does Jasper Therapeutics compare to Acrivon Therapeutics?

Summary

How does Jasper Therapeutics compare to Telomir Pharmaceuticals?

Summary

How does Jasper Therapeutics compare to Kalaris Therapeutics?

Summary

How does Jasper Therapeutics compare to Sera Prognostics?

Summary

How does Jasper Therapeutics compare to iBio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JSPR vs. The Competition

Jasper Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Jasper Therapeutics (JSPR) Competitors

JSPR vs. ACRV, TELO, KLRS, SERA, and IBIO

How does Jasper Therapeutics compare to Acrivon Therapeutics?

Which has higher valuation & earnings, JSPR or ACRV?

Does the media prefer JSPR or ACRV?

Do analysts prefer JSPR or ACRV?

Is JSPR or ACRV more profitable?

Which has more risk & volatility, JSPR or ACRV?

Do insiders and institutionals believe in JSPR or ACRV?

Summary

How does Jasper Therapeutics compare to Telomir Pharmaceuticals?

Is JSPR or TELO more profitable?

Do insiders and institutionals believe in JSPR or TELO?

Do analysts rate JSPR or TELO?

Does the media prefer JSPR or TELO?

Which has better earnings and valuation, JSPR or TELO?

Which has more risk and volatility, JSPR or TELO?

Summary

How does Jasper Therapeutics compare to Kalaris Therapeutics?

Which has more risk and volatility, KLRS or JSPR?

Is KLRS or JSPR more profitable?

Which has preferable valuation and earnings, KLRS or JSPR?

Does the media favor KLRS or JSPR?

Do analysts recommend KLRS or JSPR?

Do institutionals & insiders hold more shares of KLRS or JSPR?

Summary

How does Jasper Therapeutics compare to Sera Prognostics?

Which has more volatility and risk, JSPR or SERA?

Do insiders and institutionals have more ownership in JSPR or SERA?

Is JSPR or SERA more profitable?

Which has preferable earnings and valuation, JSPR or SERA?

Does the media refer more to JSPR or SERA?

Do analysts rate JSPR or SERA?

Summary

How does Jasper Therapeutics compare to iBio?

Do institutionals and insiders believe in IBIO or JSPR?

Which has better earnings & valuation, IBIO or JSPR?

Do analysts prefer IBIO or JSPR?

Is IBIO or JSPR more profitable?

Does the media prefer IBIO or JSPR?

Which has more volatility and risk, IBIO or JSPR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JSPR vs. The Competition

Jasper Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools